Laboratorios Farmaceuticos Rovi, S.A. Share Price
Stocks
ROVI
ES0157261019
Pharmaceuticals
OTC Markets Traded|
Market Closed -
BME
09:05:15 23/09/2026 pm IST
|
After hours 12:42:40 am | |||
| 59.25 EUR | +0.25% |
|
58.75 | -0.84% |
| 23/07 | Laboratorios Farmaceuticos Rovi, S.A., H1 2026 Earnings Call, Jul 23, 2026 | |
| 23/07 | Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| Market Cap | 302.26Cr 344.37Cr 284.12Cr 259.76Cr 485.41Cr 33TCr 489.01Cr 3.41TCr 1.32TCr 17TCr 1.29TCr 1.26TCr 55TCr | P/E 2026 * |
20x | P/E 2027 * | 17.5x |
|---|---|---|---|---|---|
| Enterprise Value | 301.41Cr 343.4Cr 283.32Cr 259.03Cr 484.04Cr 33TCr 487.63Cr 3.4TCr 1.32TCr 17TCr 1.29TCr 1.26TCr 54TCr | EV / Sales 2026 * |
3.89x | EV / Sales 2027 * | 3.31x |
| Free-Float |
31.63% | Yield 2026 * |
1.65% | Yield 2027 * | 1.97% |
| Markets | Quality | ||
|---|---|---|---|
BME
| ROVI | Delayed | |
CBOE
| ROVIe | Real-time | |
|
Tradegate
| 41L | Real-time | |
|
OTC Markets
| LABFF | Delayed | |
|
Berne S.E.
| 41L | End-of-day quote | |
|
Deutsche Boerse AG
| 41L | Delayed | |
|
CBOE
| 0ILL | Real-time | |
|
Börse Stuttgart
| 41L | Delayed | |
|
Boerse Muenchen
| 41L | Real-time | |
|
Wiener Boerse
| ROVI | End-of-day quote | |
|
Borsa Italiana
| 1ROVI | End-of-day quote |
Last Transcript: Laboratorios Farmaceuticos Rovi, S.A.
| 1 day | -0.59% | ||
| 1 week | +1.72% | ||
| Current month | -2.23% | ||
| 1 month | -1.00% | ||
| 3 months | +0.25% | ||
| 6 months | -24.04% | ||
| Current year | -6.69% |
| 1 week | 57.45 |  | 59.9 |
| 1 month | 56.95 | | 62.2 |
| Current year | 53.1 | | 86.7 |
| 1 year | 53.1 | | 86.7 |
| 3 years | 45.52 | | 94.8 |
| 5 years | 35.2 | | 94.8 |
| 10 years | 10.8 | | 94.8 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 27/07/2007 | |
| Director of Finance/CFO | - | 01/01/2001 | |
| Chief Operating Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | - | 17/07/2021 | |
| Director/Board Member | - | 27/07/2007 | |
| Director/Board Member | - | 27/07/2007 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 23/06/23 | Buy | Director | 1,000 | 0.0019% | ||
| 13/04/22 | Norbel Inversiones SL
| Sell | Company | 5,60,690 | 1.0000% | |
| 15/03/22 | Norbel Inversiones SL
| Sell | Company | 28,03,448 | 5.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.25% | +1.72% | +1.02% | +14.16% | 345.87Cr | |
| -1.15% | +1.60% | +54.75% | +109.31% | 1,04300Cr | |
| -0.15% | +0.41% | +51.98% | +67.46% | 65TCr | |
| +0.06% | +0.86% | +18.94% | +71.21% | 47TCr | |
| -0.25% | +0.19% | +36.95% | +45.54% | 35TCr | |
| +0.98% | +2.91% | +20.59% | +27.14% | 27TCr | |
| -1.91% | +2.42% | +10.41% | +11.04% | 26TCr | |
| -0.34% | +8.41% | +42.25% | +52.89% | 22TCr | |
| -1.58% | +1.86% | +31.49% | +101.02% | 19TCr | |
| -2.53% | -7.47% | -32.63% | -60.41% | 18TCr | |
| Average | -0.69% | +2.19% | +23.58% | +43.94% | 36.36TCr | |
| Weighted average by Cap. | -0.63% | +2.19% | +35.94% | +65.40% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 77Cr 88Cr 73Cr 67Cr 124.31Cr 8.45TCr 125.23Cr 873.97Cr 338.81Cr 4.31TCr 331.19Cr 323.93Cr 14TCr | 89Cr 101.68Cr 84Cr 77Cr 143.32Cr 9.74TCr 144.38Cr 1.01TCr 390.62Cr 4.97TCr 381.83Cr 373.46Cr 16TCr |
| Net income | 15Cr 17Cr 14Cr 13Cr 23Cr 1.6TCr 24Cr 165.13Cr 64Cr 813.78Cr 63Cr 61Cr 2.64TCr | 17Cr 20Cr 16Cr 15Cr 28Cr 1.89TCr 28Cr 195.2Cr 76Cr 961.99Cr 74Cr 72Cr 3.12TCr |
| Net Debt | -84.99L -96.84L -79.89L -73.04L -1.36Cr -93Cr -1.38Cr -9.6Cr -3.72Cr -47Cr -3.64Cr -3.56Cr -153.34Cr | -7.25Cr -8.26Cr -6.82Cr -6.23Cr -12Cr -791.34Cr -12Cr -82Cr -32Cr -403.45Cr -31Cr -30Cr -1.31TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/26/23 | €59.25 | +0.25% | 80,397 |
| 22/26/22 | €59.10 | +0.42% | 87,377 |
| 21/26/21 | €58.85 | +2.08% | 80,702 |
| 18/26/18 | €57.65 | -1.71% | 98,680 |
| 17/26/17 | €58.65 | +0.69% | 64,260 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ROVI Stock
Select your edition
All financial news and data tailored to specific country editions
